See the latest news and media coverage for ExpreS2ion. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing immunotherapies and vaccines
expres2ionbio.comLast updated
In short: ExpreS2ion fully enrolled ES2B-C001 Phase I trial and raised SEK 19.3 million in a directed share issue.
The biotech company utilized a guarantee undertaking with Vator Securities to finalize funding, resulting in significant share dilution while advancing its lead asset's Phase I clinical trials.
ExpreS2ion obtains warrants guarantee and enters a SEK 50M put option agreement with Alumni Capital to fund Phase I trials and maintain financial flexibility.
The company reported SEK 34.4m cash balance and completed financing for its current program. Phase I trial ES2B-C001 showed strong anti-HER2 responses without dose-limiting toxicities.
DSMB recommended expanding the 450 μg cohort; antibody responses were seen in 12 of 13 evaluable patients. Phase II initiation is now targeted for H2 2027.
Hørsholm, Denmark, 5 October 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, pursuant to the...
Risk warning: Trading in financial instruments and/or cryptocurrencies is associated with a high risk, such as the chance that you will lose all or part of the...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
Hørsholm, Denmark, 12 August 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel ...
Track ExpreS2ion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ExpreS2ion and other trending companies.
